Chhaya: a review of India's unique non-hormonal oral contraceptive
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20263081Keywords:
Centchroman, Chhaya, Non-hormonal contraceptive, Postpartum contraception, India, Family planningAbstract
Centchroman, which is also marketed as “Chhaya” under the National Family Planning Programme of India. It is the world's only non-steroidal, non-hormonal, once-weekly oral contraceptive. It was first synthesised at the Central Drug Research Institute (CDRI), Lucknow in 1967 and licensed in 1991. Later in April 2016, Chhaya was introduced free of cost into India's national family plaining programme. Despite the safety profile, its uptake remains far below its potential. This review synthesizes the published Indian evidence on the clinical efficacy, safety, acceptability, and programmatic challenges of centchroman as a contraceptive, with an emphasis on the postpartum and post-abortion contexts. A narrative review of peer-reviewed studies, government guidelines, and quality-improvement (QI) initiatives conducted in India was performed. Across the studies, Pearl Index values ranged from 0.2 to 2.0 per hundred woman-years, satisfaction rates reach 77-95%, and delayed or irregular menses is the most consistently reported side effect (8-26%). Access barriers and preference for alternative methods are the leading reasons for discontinuation. QI interventions that emphasize structured counselling and supply-chain strengthening have dramatically increased acceptance rates. Centchroman is a safe, effective, and reversible contraceptive that occupies a unique niche in India's family planning landscape. Programmatic investment in counselling, drug availability, and mHealth support is needed to translate its pharmacological promise into wider use.
References
Background for Family Planning: National Health Mission. Available from: https://nhm.gov.in/nhm/index1.php?lang=1&level=1&lid=398&sublinkid=365&utm. Accessed on 24 April 2026.
NFHS 5 Report. 2021. Available at: https://dhsprogram.com/pubs/pdf/FR375/FR375.pdf. Accessed on 24 April 2026.
Weisband YL, Keder LM, Keim SA, Gallo MF. Postpartum intentions on contraception use and method choice among breastfeeding women attending a university hospital in Ohio: a cross-sectional study. Reprod Health. 2017;14:45.
Contraceptives, Oral, Combined. In: Drugs and Lactation Database (LactMed®). Bethesda (MD): National Institute of Child Health and Human Development. 2006.
Kamboj VP, Ray S, Anand N. Centchroman: A safe reversible postcoital contraceptive with curative and prophylactic activity in many disorders. Front Biosci. 2018;10(1):1-14.
Kabra R, Allagh KP, Ali M, Jayathilaka CA, Mwinga K, Kiarie J. Scoping review to map evidence on mechanism of action, pharmacokinetics, effectiveness and side effects of centchroman as a contraceptive pill. BMJ Open. 2019;9(10):e030373.
World’s first non-steroidal birth control pill. Council of Scientific Industrial Research. Available at: https://www.csir.res.in/en/csir-success-stories/worlds-first-non-steroidal-birth-control-pill. Accessed on 24 April 2026.
Miuli I, Dewan R, Agarwal K. A study to compare acceptability, safety and continuation rates of combined hormonal pill and centchroman as post abortion contraceptives. Int J Reprod Contracept Obstet Gynecol. 2020;9(8):3350-9.
Yadav P, Sharma KA, Singh P, Bhatt N, Kulshrestha V, Karna P, et al. Assessing the Acceptance of and Compliance with Centchroman Usage, a Non-hormonal Contraceptive Pill, Among Postpartum Women: A Cross-Sectional Study at a Tertiary Care Centre in North India. Cureus. 2026;18(2):e103611.
Radhika AG, Suneja A, Malik H, Gupta R. QI initiative to improve utilization of centchroman: a non-steroidal contraceptive. Int J Reproduct Contracept Obstet Gynecol. 2022;11(11):3068-73.
Nair1 HS, Jayasimhan2 P. A Prospective Study of Centchroman Users with Special Reference to Its Contraceptive Benefit. J Evid Based Med Healthc. 2016;3(12):1-7.
Doke G, Kamda J. A study of Centchroman users with special reference to its contraceptive benefit. Int J Reprod Contracept Obstet Gynecol. 2019;8(11):4204.
Singh MM. Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders. Med Res Rev. 2001;21(4):302-47.
Agarwal K, Dewan R. Evaluation of acceptability, safety, and continuation rates of centchroman as postabortion nonsteroidal contraceptive pill. Contraception. 2023;121:109961.
Gupta RC, Paliwal JK, Nityanand S, Asthana OP, Lal J. Centchroman: a new non-steroidal oral contraceptive in human milk. Contraception. 1995;52(5):301-5.
Paliwal JK, Grover PK, Asthana OP, Nityanand S, Gupta RC. Excretion of centchroman in breast milk. Br J Clin Pharmacol. 1994;38(5):485-6.
Gupta M, Bansiwal R, Anand HP. Comparison of centchroman and PPIUCD in terms of efficacy, safety and continuation rate in immediate postpartum period. Int J Reprod Contracept Obstet Gynecol. 2021;10(1):203-6.
Radhika AG, Suneja A, Gupta R, Dorairajan G, Aggarwal P, Ashok V, et al. Clinical outcomes among Centchroman users across six medical college hospitals in India. Int J Gynecol Obstet. 2025;170(3):1153-61.
Sarkar A, Wadhawan I, Raj A, Nagabhushana P, Singh P. Improving the Acceptance Rate of Centchroman as a Postpartum Contraceptive Through a Quality Improvement Initiative. Cureus. 2022;14(9):e29277.
Xess S, Kujur A, Kanwar G, Claudius E, Toppo SM. Quality Improvement Initiative to Increase the Acceptance Rate of Tablet Chhaya (Centchroman) In the Immediate Postpartum Period in the Tertiary Care Centre of RSDKS GMC Ambikapur. Int J Acad Med Pharm. 2024;6(5):273-6.
Why India’s family planning policy must place “Chhaya” at the centre. Available at: https://www.frhsi.org.in/Chhaya.php. Accessed on 12 May 2026.
Downloads
Published
How to Cite
Issue
Section
